GlassScriptPhysician profile
Matthew J Smith
NPI 1295774826
$4,615.63
in general payments reported to CMS, 2019-2025
19 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $780 · 2023: $873 · 2024: $1,550 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,487 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,486.59 |
| Education | $209.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,144.69 | 2021-2025 | |
| Genzyme Corporation | $605.94 | 2021-2025 | |
| Ucb, INC. | $453.44 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $318.96 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $307.04 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $281.54 | 2021-2025 | Libtayo |
| Arcutis Biotherapeutics, INC. | $247.37 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $219.29 | 2022-2025 | |
| Pfizer INC. | $190.34 | 2021-2025 | |
| Galderma Laboratories, L.P. | $179.29 | 2022-2025 | Nemluvio, Dysport |
| Leo Pharma INC. | $177.49 | 2023-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.32 | 2023-2024 | Spevigo |
| Lilly USA, LLC | $113.46 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $100.85 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $31.16 | 2023 | Sotyktu |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $27.69 | 2025 | |
| Depuy Synthes Sales INC. | $27.22 | 2025 | Na |
| Strata Skin Sciences, INC. | $26.70 | 2024 | Xtrac |
| Verrica Pharmaceuticals INC. | $19.84 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.